This HTML5 document contains 220 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n12http://dx.doi.org/10.1186/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
n10https://scigraph.springernature.com/pub.10.1186/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q36245341
rdf:type
wikibase:Item
schema:description
2012年學術文章 2012年学术文章 სამეცნიერო სტატია 2012年學術文章 videnskabelig artikel (udgivet 2012) artikull shkencor artículu científicu espublizáu en 2012 научная статья bilimsel makale 2012 nî lūn-bûn 2012年学术文章 наукова стаття, опублікована в травні 2012 مقالة علمية نشرت بتاريخ 2-5-2012 vitskapeleg artikkel article científic научни чланак מאמר מדעי мақолаи илмӣ teaduslik artikkel vedecký článok 2012年學術文章 ২০১২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ artigo científico επιστημονικό άρθρο articol științific vitenskapelig artikkel artigo científico (publicado na 2012) мақолаи илмӣ bài báo khoa học 2012年の論文 գիտական հոդված scientific article 2012년 논문 2012年學術文章 articolo scientifico 2012年学术文章 artykuł naukowy научна статия artículo científico publicado en 2012 научни чланак 2012年学术文章 2012年學術文章 artikulong pang-agham سائنسی مضمون vetenskaplig artikel article scientific مقالهٔ علمی wetenschappelijk artikel 2012年学术文章 mokslinis straipsnis article scientifique (publié 2012) vědecký článek naučni članak artigo científico (publicado na 2012) scienca artikolo wissenschaftlicher Artikel บทความทางวิทยาศาสตร์ 2012年學術文章 tudományos cikk tieteellinen artikkeli
p:P577
wds:Q36245341-61EC5D12-20D0-4C1B-95A0-271A29F45977
wdt:P577
2012-05-02T00:00:00Z
p:P2888
wds:Q36245341-A8E1846B-AB39-4B16-A920-250E40D934EF
wdt:P2888
n10:bcr3179
p:P2860
wds:Q36245341-2CCE7E19-4619-4B02-98A3-9747FBB4E345 wds:Q36245341-2D35963D-362B-4C1C-9990-09C2F5F14820 wds:Q36245341-33DFD2BB-9456-4271-859B-D0FF2486EE4B wds:Q36245341-42A60079-18E1-4364-B64B-933939A9E6BF wds:Q36245341-12DF50E0-BF39-4F5C-9F02-B985114797C1 wds:Q36245341-1B0CA068-4EA5-445A-8ED1-5C72635023F1 wds:Q36245341-1DD0FDF5-956C-4F86-BBD3-A4CCC4D68112 wds:Q36245341-24498C8E-B27F-4DC0-9EE1-11A6861B7CEC wds:Q36245341-02B5116F-0B23-4244-A9D2-ABFAC561D16B wds:Q36245341-04E9973F-D909-422C-B1CC-669C49F47B13 wds:Q36245341-A91D28AF-D778-49CD-9521-92575A43ACE3 wds:Q36245341-A95A9654-C01A-433F-A552-51D405E8F975 wds:Q36245341-AA5D4A41-27D7-471C-9D71-F0709C091ADF wds:Q36245341-AC5ADDA1-0069-4489-AA0A-356756730569 wds:Q36245341-85BEEDB1-72D0-4AB2-85C7-3202632076A5 wds:Q36245341-8E207514-A725-41DC-BAEA-CD59411AE642 wds:Q36245341-8E85A72E-1443-4831-8ECC-6F69766B5D8A wds:Q36245341-9337C010-BD3D-4B32-AC3C-A3F7554EAC16 wds:Q36245341-940CBDE3-B1C1-4686-9F62-62988A32CC7C wds:Q36245341-6936BF8A-E904-4B2F-B40D-C324FEEC7827 wds:Q36245341-69813809-5F4E-4908-BA17-76CAA69E4D7F wds:Q36245341-6B2765A3-B91D-41F4-A9A2-E05BCF36FDE0 wds:Q36245341-79A05739-2882-41DD-B8EA-53DF5AEB3674 wds:Q36245341-7FDF5ABB-FF80-41B0-A712-F1E3CA6E6046 wds:Q36245341-49CBFC14-A1DE-4B26-85AF-6D074868FC5C wds:Q36245341-4DB7A457-7ACF-4833-B0C6-D7EF054499CD wds:Q36245341-61EAAD75-6E26-432C-81A0-62E64E9B55FC wds:Q36245341-EA58CC2C-F204-4334-83DD-C5D9EC9293E1 wds:Q36245341-ED95278B-E64E-4D11-A103-8DB57BEFA952 wds:Q36245341-FBB06C71-40C1-4579-BA9F-AA9E65280D67 wds:Q36245341-BF227670-48E0-460D-9D86-BADDA74F2137 wds:Q36245341-C0FE9D32-262C-4988-9F63-BD3177CAC916 wds:Q36245341-C7466D2A-9EC6-4EE1-AF81-E9FAFBEFCF55 wds:Q36245341-C7ED49AE-4C6A-491C-BDFE-97D41A3CBD0F wds:Q36245341-C9505438-2BE1-435D-B0E1-D7F853C373E1 wds:Q36245341-CEC3CBC7-1A5B-49F2-B18B-10DF8B24E399 wds:Q36245341-AD2CF2DC-4B68-402B-9AF0-14B63AB170DE wds:Q36245341-AEDD3C6C-572E-4DBD-A6DB-DEFA31A02B2A wds:Q36245341-B1B55430-1D03-4E4B-B883-1841A7276DD7 wds:Q36245341-B3C94E5D-243B-43DD-86BC-82C6A63980CD wds:Q36245341-B496BA03-405A-40EE-BC50-A5A33C4D3F57 wds:Q36245341-B4C2AC16-B5A3-4A69-BD3D-EF607617F0BC wds:Q36245341-BA95BD39-3711-4736-B2A7-F7AB09845244
wdt:P2860
wd:Q35168290 wd:Q35146274 wd:Q29547590 wd:Q42788947 wd:Q70908054 wd:Q34674699 wd:Q33687048 wd:Q30326271 wd:Q27860990 wd:Q66829419 wd:Q29616468 wd:Q33939753 wd:Q78392713 wd:Q46817262 wd:Q46691182 wd:Q33265626 wd:Q43280955 wd:Q59565353 wd:Q30479523 wd:Q42445479 wd:Q46828225 wd:Q35906287 wd:Q34234217 wd:Q33179641 wd:Q36644176 wd:Q36620640 wd:Q43546960 wd:Q37125089 wd:Q28372484 wd:Q59567679 wd:Q27824864 wd:Q52542729 wd:Q46522790 wd:Q46493659 wd:Q52561781 wd:Q44362100 wd:Q37198196 wd:Q75216726 wd:Q37206289 wd:Q35029530 wd:Q57098008 wd:Q57265716 wd:Q21092375
p:P2093
wds:Q36245341-70912DC3-65B8-4394-8BE4-7B402A52BAC1 wds:Q36245341-9D3750A8-4D3B-40AC-8A9F-6F94F0B89B67 wds:Q36245341-90959E35-AD4D-4089-870B-BCA7CC619845 wds:Q36245341-2C32E471-6A86-4BD7-B378-55F867D9C521 wds:Q36245341-BD8F218C-C172-41ED-84E9-FE36BF176A16 wds:Q36245341-B1C63175-25FA-422F-B82A-43C30711044A wds:Q36245341-F3CDCC82-E672-491A-828E-2D5F14ACE1F8 wds:Q36245341-E6ED267D-0CBC-4CC6-9D0D-59E803A9962D
wdt:P2093
Lynnette Fernández-Cuesta Priscila Falagan-Lotsch Catherine Oakman Denis Larsimont Ke-Seay Smoth M Stella Dolci John Crown Patrizia Dell'orto
rdfs:label
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
skos:prefLabel
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
schema:name
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
p:P50
wds:Q36245341-D4E247E4-40F7-488D-A9AA-5366A5A7D3C4 wds:Q36245341-0FBB5156-F773-4DB2-8BA2-FDF544AB713F wds:Q36245341-37EB0E53-B78C-4775-B35F-88B8CD298CC8 wds:Q36245341-2A536F54-92B3-4A37-AF5C-7A0239B5595C wds:Q36245341-5EBEFF53-8395-492B-9D3C-409EB804723C wds:Q36245341-45E47C61-A1DD-43F1-A0B4-B14DF69AAFCB wds:Q36245341-5A6AAAB6-4A38-4767-9E6E-D13C5F585387 wds:Q36245341-67F6EF70-FCE0-40B1-AB54-5F26623C9F8D wds:Q36245341-CA747CEE-C170-4CB9-A9D7-64A2A1FC5925
wdt:P50
wd:Q55686403 wd:Q38293745 wd:Q38291268 wd:Q57419614 wd:Q38295475 wd:Q37840836 wd:Q38293804 wd:Q80639743 wd:Q50585710
p:P1476
wds:Q36245341-E831B604-2756-4AE9-844F-3F7464AD11B2
wdt:P1476
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
p:P304
wds:Q36245341-8858F95D-2892-4812-B459-933CF5995D6A
wdt:P304
R70
p:P31
wds:Q36245341-ABA2BAC6-14E6-4BDB-A33E-6AF564CA0181
wdt:P31
wd:Q13442814
p:P921
wds:Q36245341-13AF9204-08B8-4D61-A2EC-2EFFA9686B03
wdt:P921
wd:Q42824827
p:P698
wds:Q36245341-96A7F92E-A942-41AA-A686-E9BF44A39A7E
wdtn:P698
n13:22551440
wdt:P698
22551440
p:P1433
wds:Q36245341-17BC5D6F-A269-48BB-BB47-D5538EDCFA05
wdt:P1433
wd:Q2208481
p:P433
wds:Q36245341-5D917D4F-0CA5-4F6C-8998-D31698653C2D
p:P478
wds:Q36245341-1B10DB85-5DF0-41C0-9315-7FE82DA42E2A
wdt:P433
3
wdt:P478
14
p:P356
wds:Q36245341-A4D1B46A-CDB9-49DC-B40D-DD00B4D6B034
wdtn:P356
n12:BCR3179
wdt:P356
10.1186/BCR3179
p:P5875
wds:Q36245341-16AC4E44-7F02-484F-BACB-4A8F3ACCF1DF
wdt:P5875
224887275
p:P6179
wds:Q36245341-39E6EE95-BC10-482C-9688-3B2894919E47
wdt:P6179
1012055898
p:P932
wds:Q36245341-5B4CE524-2777-4B4F-B819-EA73481B61D3
wdt:P932
3446332